

Multi-Analyst Reanalysis of IPD on Esketamine and Suicidality (Team 1)

SHARE-CTD study group

Lay summary

This study explores if and how different analytical choices may affect the results of meta-analyses using individual participant data (IPD) from clinical trials. Three independent research teams will separately analyse data on esketamine's effect on suicidal thoughts in depression, shared through the Yale Open Data Access (YODA) project. By comparing their methods, results, and interpretations, the study will test whether analytic flexibility changes scientific conclusions. The project promotes transparency, reproducibility, and more trustworthy clinical research.

Share CTD is funded by the European Union under the grant agreement Horizon-MSCA.2022-DN 101120360.

Scientific abstract

Background: The reproducibility of meta-analyses can be affected by analytical flexibility, especially in individual participant data (IPD) meta-analyses, which require complex data management and methodological decisions. The effect of such flexibility on outcomes remains underexplored.

Objective: To assess the reproducibility of independent IPD meta-analyses evaluating esketamine's efficacy in reducing suicidality among patients with major depressive disorder.

Study Design: Three independent teams from the SHARE-CTD network will conduct parallel IPD meta-analyses using a common dataset, working in isolation until a collaborative datathon, where results and methods will be compared.

Participants: IPD from all esketamine clinical trials available via the YODA project, encompassing patients with major depressive disorder.

Primary and Secondary Outcome Measure(s): Primary: Change in suicidality, assessed using standardised scales or adverse event reporting. Secondary: Variability in analytical decisions, observed results, and conclusions across teams.

Statistical Analysis: Teams will define and preregister their own analysis plans.

Reproducibility will be evaluated by comparing methodological choices, quantitative results (effect sizes, p-values, confidence intervals), and interpretations. Based on the forking path diagram, all possible combinations of analytic decisions will be run in a vibration of effects (VoE) exercise.

Acronyms	3
Background	4
Objective	4
Structure and Recruitment of Analysis Teams	5
Roles, Responsibilities, and Process.....	5
a. Research Question	5
b. Code of Conduct	6
c. Reporting Requirements	6
d. Inclusion of Analyses.....	6
e. Authorship and Attribution	6
f. Update Rights.....	6
g. Timeline.....	6
Data and Materials.....	6
Independence of Analyses	7
Sharing and Processing Results.....	7
Meta-Research and Synthesis Strategy	8
Transparency and FAIR Principles	8
References	9

SHARE-CTD study group

SHARE-CTD (Sharing and Re-using clinical trial data to maximise impact) is a doctoral network funded by the European Union that involves 11 principal investigators and 16 academic and non-academic partners. This project was motivated by the growing movement toward open science and by the need to define good practices for the preparation and use of clinical trial data. Its aim is to train a new generation of biomedical researchers with a deep understanding of the processes, values, and benefits of clinical trial data sharing. To gain a comprehensive understanding, biomedical researchers must be trained in areas such as data science, trial regulation, meta-research, as well as ethical, legal, and social issues.

Acronyms

EBM: Evidence Based Medicine

IPD: Individual participant data

OSF: Open Science Framework

PICOS: Patients Interventions Comparators Outcomes Study designe

SHARE-CTD: Sharing and Re-using clinical trial data to maximise impact

VoE: Vibration of effects

YODA Project: Yale University Open Data Access Project

Background

Meta-analyses are often placed at the top of the evidence-based medicine (EBM) hierarchy. Yet, they are published in large numbers, frequently overlapping or redundant, and sometimes producing contradictory results [1]. Such inconsistencies are concerning, given that meta-analyses are expected to be exhaustive and reproducible syntheses of the literature. However, they are retrospective exercises that involve many degrees of freedom, making them prone to vibration of effects (VoE) [2]. This phenomenon has been observed using multiverse analyses of 1/ head-to-head meta-analyses [3], 2/ indirect comparisons [4], and—though to a lesser extent—3/ individual participant data (IPD) meta-analyses [5]. However, multiverse meta-analyses rely on many meta-analyses to evaluate result variability, often taking an overly agnostic approach, with sometimes very arbitrary analytical choices. Less is known about how specific analytical scenarios and decisions—especially in data management, statistical modelling, and interpretation—can shape findings within a single research question.

IPD meta-analyses are a particularly relevant context for exploring this phenomenon, as they involve numerous analytical choices—not only in defining the research question, selecting inclusion criteria, and analyzing outcomes, but also during data management. Because IPD must be harmonized across studies, and outcomes are sometimes reconstructed when they were not originally collected for the specific purpose of the meta-analysis, these additional steps introduce further degrees of freedom that may influence results.

To explore this question, we selected the case study of esketamine's effect on suicidal ideation, drawing on our prior experience with this topic [6]. This clinically significant outcome exemplifies the many degrees of freedom involved in IPD meta-analyses making it an ideal example to investigate how analytical decisions can influence results.

The SHARE-CTD datathons provide a unique opportunity to investigate these issues in a many-analyst framework [7], helping to better understand the role of analytical flexibility in IPD meta-analysis.

Objective

To explore the reproducibility of independent analyses conducted by three teams performing an individual participant data (IPD) meta-analysis assessing the efficacy of esketamine in reducing suicidality among patients with major depressive disorder. Clinical trial data will be sourced via the YODA project.

Reproducibility of those analyses will be assessed along three key dimensions, as defined by Fanelli et al. [8]:

- **Methods reproducibility** (consistency in analytic procedures),
- **Results reproducibility** (consistency in quantitative outcomes), and
- **Inferential reproducibility** (consistency in interpretation and conclusions).

Structure and Recruitment of Analysis Teams

- **Composition:** Three independent teams from the SHARE-CTD network, each consisting of 3–4 analysts (including at least one with biostatistical expertise), and one senior researcher with domain expertise in psychiatry or psychopharmacology (IAC, FN, MP).
- **Rationale:** IPD meta-analyses demand diverse competencies spanning data management, statistical methodology, and clinical knowledge. Senior researchers will serve as independent advisors—providing methodological and clinical input—but will not engage in data handling or analysis.
- **Recruitment:** All analysts will be SHARE-CTD doctoral candidates. Teams must commit to working independently until the datathon in February 2026.

Roles, Responsibilities, and Process

a. Research Question

"Does esketamine reduce suicidality in patients with depression?"

This research question is intentionally broad to allow for variation in analytic strategies (see **Box1**). It addresses a clinically relevant issue, given esketamine's U.S. approval for patients depression and suicidal ideation.

The dataset offers substantial analytical flexibility, with potential variability in:

Population: e.g., inclusion of patients with or without suicidal ideation at baseline; baseline depression; history of suicide

Intervention: different dosing regimens

Outcome: suicidality assessed through specific scales, standardisation to a Z-score or adverse event reporting

Comparator: placebo vs. active comparators (e.g., quetiapine)

Study design: double-blind, single-blind, or open-label trials

Box 1: source of analytical variability (not exhaustive)

Furthermore, members of our consortium (IAC and FN) possesses prior experience with this dataset [6]. Notably, the question pertaining to suicidality necessitated adaptations and modifications to the original protocol, underscoring the practical significance of the present study.

Despite these degrees of freedom, feasibility is enhanced by the homogeneity of the dataset: all studies originate from a single manufacturer and drug development program.

b. Code of Conduct

- All participants will sign a YODA-compliant data use agreement, including provisions for confidentiality, data security, and ethical compliance.
- Each team will preregister its statistical analysis plan (SAP) on the Open Science Framework (OSF) under embargo (to preserve independence) prior to accessing the data or initiating any analysis.

c. Reporting Requirements

- Teams will prepare a comprehensive research report detailing their SAP (including deviations), analytic decisions, results, commented code, and final conclusions.
- All code and methodological documentation will be made openly accessible upon publication.

d. Inclusion of Analyses

- All analyses submitted by the three teams will be included in the final synthesis, regardless of their methodology or findings.

e. Authorship and Attribution

- Results of the datathon will be published in a research article.
- Analysts' names will be publicly linked to their team's work, with individual contributions denoted by initials.
- All co-analysts will be included as co-authors of the final publication, provided they also meet the other criteria (approval, accountability) for being listed as an author, with contributions described using the CRediT taxonomy.

f. Update Rights

- Teams may update their analyses before the February 2026 datathon, provided all changes are transparently documented.
- During the datathon, analyses will be finalised, presented, compared, and discussed with other teams and SHARE-CTD principal investigators. No further modifications will be permitted after this meeting.

g. Timeline

- **Anticipated data access and start of analyses:** December 2025
- **Datathon and synthesis workshop:** February 2026

Data and Materials

- **Datasets:** IPD from all esketamine trials available via the YODA project, accompanied by study protocols, variable dictionaries, and relevant metadata. All available studies are listed here: <https://yoda.yale.edu/trials-by-generic-name/>

Identifier	Enrollment
NCT04599855	477
NCT04338321	676
NCT03434041	252
NCT02497287	802
NCT02493868	719
NCT01998958	108
NCT02918318	202
NCT01627782	68
NCT01640080	30
NCT03097133	230
NCT02133001	68
NCT03039192	226
NCT02422186	139
NCT02418585	236
NCT02417064	346

Table 1: available studies

- **Training and Access:** All teams must complete the YODA training and sign the data use agreement before receiving access.
- **Analytic Task:** Each team will define and justify their PICOS criteria and analytic methods in their preregistered SAP.

Independence of Analyses

- **Before the Datathon:** Teams must work in isolation, with no inter-team communication regarding data analysis until the February 2026 datathon (9-13 january).
- **During the Datathon:** Teams will present their results, compare methods, identify discrepancies, and collaboratively assess methodological variability.

Sharing and Processing Results

Each team will provide the lead team with:

- Final results
- Cleaned and annotated code (or step-by-step descriptions for GUI-based software)
- A narrative linking findings to conclusions

By the end of the datathon, the lead team will archive the (aggregated) data and results with restricted access. All materials will be publicly released afterward as part of post-datathon activities.

Meta-Research and Synthesis Strategy

Submitted analyses will be compared along three dimensions of reproducibility:

- **Methods Reproducibility:**
 - All methodological choices will be qualitatively analyzed and described, for instance using a “forking path diagram.” This will include:
 - Defined PICOS (Population, Intervention, Comparator, Outcomes, Study design);
 - Statistical analysis plans and methods;
 - Tools and software used;
 - Any additional options that may be identified.
- **Results Reproducibility:**
 - Consistency across analyses will be assessed using the following approach. Each analysis will be summarized in terms of (i) its conclusion (positive or negative), (ii) p-value, (iii) effect size (with outcome details), and (iv) any deviations from the initial protocol regarding the primary outcome. (v) uncertainty estimate (e.g., Confidence Interval).
 - Based on the forking path diagram, all possible combinations of analytic decisions will be run in a vibration of effects (VoE) exercise. A volcano plot will display effect sizes on the x-axis and p-values on the y-axis. We will quantify the VoE by calculating:
 - The range of p-values (RP);
 - The difference between the 99th and 1st percentile of the $-\log(\text{p-value})$;
 - The range of effect sizes;
 - The Janus effect (if the 1st and 99th percentiles of the effect size are in opposite directions).
- **Inferential Reproducibility:**
 - Differences in interpretation and clinical implications will be explored collaboratively during the datathon. As interpretation of a meta-analysis involves clinical judgment and cannot rely solely on quantitative metrics, a structured discussion among co-analysts and SHARE-CTD PIs will take place. This discussion, grounded in both quantitative results and expert clinical perspectives, will assess whether observed differences in results could meaningfully lead to different conclusions or clinical recommendations

Transparency and FAIR Principles

- All code will be shared in accordance with the FAIR principles (Findable, Accessible, Interoperable, Reusable).
- Clear guidance will be provided for researchers seeking to access the data.
- Materials will be hosted on open-access repositories (e.g., OSF).
- This protocol will be publicly available (no embargo) via the OSF as the master project document.
- The study’s conduct and reporting will adhere to the principles outlined in a recent consensus-based framework for multi-analyst studies [9].
- The teams will be asked to provide a description of usage of and prompts for artificial intelligence for this project, in particular drafting and revision of the protocol and statistical analysis plan, statistical code, presentation.

References

1. Ioannidis JP: **The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.** *Milbank Q* 2016, **94**(3):485-514.
2. Vinatier C, Hoffmann S, Patel C, DeVito NJ, Cristea IA, Tierney B, Ioannidis JPA, Naudet F: **What is the vibration of effects?** *BMJ Evid Based Med* 2025, **30**(1):61-65.
3. El Bahri M, Wang X, Biaggi T, Falissard B, Naudet F, Barry C: **A multiverse analysis of meta-analyses assessing acupuncture efficacy for smoking cessation evidenced vibration of effects.** *J Clin Epidemiol* 2022, **152**:140-150.
4. Vinatier C, Palpacuer C, Scanff A, Naudet F: **Vibration of effects resulting from treatment selection in mixed-treatment comparisons: a multiverse analysis on network meta-analyses of antidepressants in major depressive disorder.** *BMJ Evid Based Med* 2024, **29**(5):324-332.
5. Gouraud H, Wallach JD, Boussageon R, Ross JS, Naudet F: **Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis.** *BMJ Med* 2022, **1**(1):e000154.
6. Naudet F, Pellen C, Fodor LA, Gastaldon C, Barbui C, Turner EH, Le Pabic E, Cristea IA: **Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a Systematic Review with an Individual Patient Data Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials.** *medRxiv* 2025:2025.2007.2017.25331696.
7. Mansmann U, Locher C, Prasser F, Weissgerber T, Sax U, Posch M, Decullier E, Cristea IA, Debray TPA, Held L *et al*: **Implementing clinical trial data sharing requires training a new generation of biomedical researchers.** *Nature Medicine* 2023, **29**(2):298-301.
8. Goodman SN, Fanelli D, Ioannidis JP: **What does research reproducibility mean?** *Sci Transl Med* 2016, **8**(341):341ps312.
9. Aczel B, Szaszi B, Nilsson G, van den Akker OR, Albers CJ, van Assen MALM, Bastiaansen JA, Benjamin D, Boehm U, Botvinik-Nezer R *et al*: **Consensus-based guidance for conducting and reporting multi-analyst studies.** *eLife* 2021, **10**:e72185.